Please assess the completion status of the following clinical trial:

Trial Title: Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have carcinoma of unknown primary site after the following diagnostic procedures have been performed and are unrevealing of a primary site:~   * Complete medical history and physical examination,~  * Complete blood counts, chemistry profile,~  * CT scans of the chest and abdomen,~  * Directed evaluation of any symptomatic areas,~  * PET scan (recommended).~2. Patients must have biopsy-proven metastatic carcinoma, with any of the following light microscopic histologies:~   * Adenocarcinoma,~  * Poorly differentiated adenocarcinoma,~  * Poorly differentiated carcinoma (all patients with poorly differentiated carcinoma must have immunoperoxidase stains to rule out other treatable malignancies \[e.g., lymphoma, neuroendocrine carcinoma\]),~  * Poorly differentiated squamous carcinoma.~3. Patients must have biopsy material available from a surgical biopsy, a core needle biopsy, or a fine needle aspiration biopsy to provide an adequate specimen (must be 40% tumor) for the molecular profiling assay.~4. An ECOG performance status 0, 1, or 2.~5. No previous treatment with any systemic therapy.~6. Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST).~7. Laboratory values as follows:~   * WBC 4000/micro L,~  * Platelets 100,000/micro L,~  * Serum bilirubin \<1.5 times the institutional upper limits of normal (ULN),~  * Serum creatinine \< 2.0 mg/dL.~8. Patients with brain metastases are eligible only if all lesions have been controlled by surgical resection or radiation therapy, the patient is not steroid-dependent, and the patient meets all other eligibility criteria.~9. Patients must be \> 4 weeks from any major operative procedure.~10. To be eligible for the TREATMENT portion of the study, patients must have one of the five following diagnoses: colorectal, pancreas, NSCLC, ovary, renal cancer.~11. Patients must be able to understand the nature of this study and give written informed consent.~Exclusion Criteria:~1. Patients with the following specific syndromes are not eligible:~   * Patients with neuroendocrine carcinoma,~  * Women with adenocarcinoma isolated to axillary lymph nodes,~  * Women with adenocarcinoma isolated to peritoneal involvement,~  * Patients with carcinoma involving only 1 site, with resectable tumor at that site, or~  * Patients with squamous carcinoma limited to cervical, supraclavicular, or inguinal lymph nodes.~2. Patients with uncontrolled brain metastases and all patients with meningeal metastases.~3. Patients with insufficient biopsy material available for molecular profiling assay.~4. Women who are pregnant or lactating. All females of child-bearing potential must have a negative serum or urine pregnancy tests within 7 days prior to study treatment.~5. Men and women of childbearing potential are required to use effective methods of contraception during this study and for 6 months after ending therapy.~6. Patients who have received any other experimental drug within 28 days of starting treatment.~Exclusion Criteria for All Patients Receiving Bevacizumab-Containing Regimens~1. Patients with history of acute myocardial infarction within 6 months, other clinically significant cardiovascular disease (e.g., unstable angina, New York Heart Association \[NYHA\] grade 2 congestive heart failure \[CHF\], serious cardiac arrhythmias requiring medication) or \> grade 2 vascular disease.~2. Patients with uncontrolled hypertension (systolic blood pressure \[BP\] 150 or diastolic BP \>100mm Hg) or uncontrolled cardiac arrhythmias.~3. Prior hypertensive crisis or hypertensive encephalopathy.~4. Patients with clinical history of hemoptysis (defined as bright red blood of~   ½ teaspoon per episode) or hematemesis within 1 month prior to Day 1.~5. Patients with PEG tubes or G tubes.~6. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study.~7. Core biopsy or other minor surgical procedure excluding placement of a vascular access device, within 7 days prior to Day 1.~8. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1.~9. Patients with proteinuria (1000 mg/24 hours) at screening will be excluded. A 24-hour urine collection is not required in all patients (e.g., patients whose treatment plans exclude bevacizumab); however, all patients receiving bevacizumab with 1+ proteinuria on dipstick urinalysis at study entry must have a subsequent 24-hour urine collection.~10. Patients with any non-healing wound, ulcer, or long bone fracture.~11. Patients with any history of a bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).~12. Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.~13. Patients with a history of stroke or transient ischemic attach within 6 months prior to first bevacizumab dose.~14. Known hypersensitivity to any component of bevacizumab.~15. Patients with history of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a novel regimen, or that might affect the results of this study or render the subject at high risk for treatment complications.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Paclitaxel, Carboplatin, Bevacizumab and Erlotinib (Type: EXPERIMENTAL): Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
- Treatment determined by physician (Type: OTHER): Other treatment determined by physician based on molecular profiling assay

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete